News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,590 Results
Type
Article (8018)
Company Profile (140)
Press Release (476335)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166751)
Career Advice (305)
Deals (25739)
Drug Delivery (7)
Drug Development (52876)
Employer Resources (14)
FDA (9760)
Job Trends (8574)
News (238196)
Policy (17906)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (485)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33155)
ALS (104)
Alzheimer's disease (975)
Antibody-drug conjugate (ADC) (262)
Approvals (10369)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6958)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (507)
Cancer (3632)
Cardiovascular disease (217)
Career advice (245)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (476)
Cervical cancer (34)
Clinical research (47848)
Collaboration (1241)
Commercialization (3)
Compensation (1452)
Complete response letters (34)
COVID-19 (754)
CRISPR (63)
C-suite (739)
Cystic fibrosis (85)
Data (5629)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4178)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73700)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87588)
Executive appointments (698)
FDA (12372)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (911)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (289)
Government (941)
Grass and pollen (2)
Guidances (281)
Healthcare (9314)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (156)
Infectious disease (942)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (505)
Lymphoma (250)
Machine learning (27)
Management (3)
Manufacturing (528)
Marketing (8)
MASH (118)
Medical device (8652)
Medtech (8792)
Mergers & acquisitions (14379)
Metabolic disorders (704)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1819)
NextGen: Class of 2026 (3151)
Non-profit (841)
Obesity (223)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (472)
Patient recruitment (503)
Peanut (31)
People (41213)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15459)
Phase 2 (21369)
Phase 3 (14391)
Pipeline (7261)
Policy (18)
Postmarket research (1570)
Preclinical (6537)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3019)
Recruiting (6)
Regulatory (14799)
Reports (20)
Research institute (581)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (121)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Supply chain (50)
Vaccines (318)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (49)
Last 7 days (421)
Last 30 days (1626)
Last 365 days (19076)
2026 (12125)
2025 (19251)
2024 (22988)
2023 (26538)
2022 (34587)
2021 (37167)
2020 (33468)
2019 (23257)
2018 (17468)
2017 (18767)
2016 (17917)
2015 (24264)
2014 (21683)
2013 (18137)
2012 (20222)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (17880)
Australia (2097)
California (11914)
Canada (3128)
China (518)
Colorado (482)
Connecticut (408)
Delaware (208)
Europe (24617)
Florida (1783)
Georgia (376)
Hawaii (3)
Idaho (46)
Illinois (695)
India (48)
Indiana (314)
Iowa (14)
Japan (398)
Kansas (101)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1198)
Massachusetts (7833)
Michigan (307)
Minnesota (559)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2615)
New Mexico (12)
New York (2814)
North Carolina (1269)
North Dakota (4)
Northern California (5965)
Ohio (276)
Oklahoma (14)
Oregon (16)
Pennsylvania (2246)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4947)
Tennessee (119)
Texas (1930)
United States (38721)
Utah (358)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (923)
West Virginia (1)
Wisconsin (73)
484,590 Results for "myomo inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Colait and Myomo Launch Collaborative Research Initiative to Advance Understanding of Unmet Needs in Chronic Stroke
Colait today announced a collaboration with Myomo to co-sponsor research focused on the needs of individuals living with stroke-related upper limb paralysis.
June 11, 2026
·
1 min read
Press Releases
Myomo Reports Second Quarter 2026 Financial and Operating Results
August 5, 2026
·
15 min read
Press Releases
Myomo Announces Participation in Upcoming May 2026 Investor Conferences
May 14, 2026
·
1 min read
Press Releases
Myomo Reports First Quarter 2026 Financial and Operating Results
May 8, 2026
·
14 min read
Press Releases
Myomo Reports Third Quarter 2025 Financial and Operating Results
November 10, 2025
·
16 min read
Press Releases
Myomo Launches the MyoPro® 2x
April 30, 2025
·
3 min read
Business
Myomo Reports First Quarter 2024 Financial Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2024.
May 8, 2024
·
14 min read
Business
Myomo to Report First Quarter Financial Results on May 8, 2024
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2024 on May 8, 2024.
May 1, 2024
·
2 min read
Business
Myomo to Report Fourth Quarter Financial Results on March 7, 2024
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”) today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024.
February 29, 2024
·
2 min read
Genetown
Myomo to Present at the Sidoti Virtual Investor Conference on June 12-13, 2024
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, chairman and chief executive officer and David Henry, chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Virtual Investor conference being held on June 12-13, 2024.
June 5, 2024
·
1 min read
1 of 48,459
Next
